OnaBoNT-A
Phase 3Biologic
IpsenOnaBoNT-A is one of 41 biologic programs targeting Cerebral Palsy. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Myrbetriq
AstellasApproved
Vesicare
AstellasApproved
Enablex
AbbVieApproved
Detrol La
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Toviaz
PfizerApproved
Flomax
SanofiApproved
Cialis
Eli LillyApproved
Oxytrol
WWim Janssens
Approved
Levitra
BayerApproved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Overactive Bladder1 trial
Cerebral Palsy1 trial
Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Completed·—··NCT06101160·61 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OnaBoNT-A. EMBL-EBI & Wellcome Sanger Institute.
- [4]